EFFECT OF SGLT-2 INHIBITORS, GLP-1 RECEPTOR AGONISTS ON CARDIOVASCULAR AND RENAL OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES, NAFLD, AND CHRONIC KIDNEY DISEASE: A REAL WORLD EVIDENCE

被引：0
|
作者：
Krishnan, Arunkumar
Mukherjee, Diptasree
Althwanay, Aldanah
Woreta, Tinsay A.
Alqahtani, Saleh A.
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1558
引用
收藏
页码：S474 / S475
页数：2
相关论文
共 50 条
  • [1] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [2] Cardiovascular outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real life
    Fadini, G.
    Longato, E.
    Di Camillo, B.
    Sparacino, G.
    Gubian, L.
    Avogaro, A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S61 - S61
  • [3] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
    Davila, Esteban
    Mccormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
  • [4] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [5] Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Prattichizzo, Francesco
    Candia, Paola de
    Ceriello, Antonio
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 120
  • [6] Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
    Yamada, Takayuki
    Wakabayashi, Mako
    Bhalla, Abhinav
    Chopra, Nitin
    Miyashita, Hirotaka
    Mikami, Takahisa
    Ueyama, Hiroki
    Fujisaki, Tomohiro
    Saigusa, Yusuke
    Yamaji, Takahiro
    Azushima, Kengo
    Urate, Shingo
    Suzuki, Toru
    Abe, Eriko
    Wakui, Hiromichi
    Tamura, Kouichi
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [7] Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
    Takayuki Yamada
    Mako Wakabayashi
    Abhinav Bhalla
    Nitin Chopra
    Hirotaka Miyashita
    Takahisa Mikami
    Hiroki Ueyama
    Tomohiro Fujisaki
    Yusuke Saigusa
    Takahiro Yamaji
    Kengo Azushima
    Shingo Urate
    Toru Suzuki
    Eriko Abe
    Hiromichi Wakui
    Kouichi Tamura
    Cardiovascular Diabetology, 20
  • [8] Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
    Georgianos, Panagiotis I.
    Vaios, Vasilios
    Roumeliotis, Stefanos
    Leivaditis, Konstantinos
    Eleftheriadis, Theodoros
    Liakopoulos, Vassilios
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
  • [9] Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
    Longato, Enrico
    Di Camillo, Barbara
    Sparacino, Giovanni
    Gubian, Lorenzo
    Avogaro, Angelo
    Fadini, Gian Paolo
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
  • [10] SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Shaughnessy, Allen F.
    AMERICAN FAMILY PHYSICIAN, 2021, 104 (02) : 206 - 206
12345